Sen. Feinstein’s Cosmetics Safety Bill Launches With GOP Cosponsor

21 Apr 2015

The Personal Care Products Safety Act would preempt duplicative state-level requirements for ingredient use and manufacturer responsibilities, addressing what has become one of the foremost banes of industry in recent years, while increasing FDA’s authority over the sector and giving it new responsibilities with regard to ingredient safety review. Additional compliance requirements for industry could prove challenging, but the positive PR likely to result from the legislation could help soften the blow.

The Personal Care Products Safety Act, introduced April 20 by Sens. Dianne Feinstein, D-Calif., and Susan Collins, R-Maine, would require cosmetics firms to comply with regulations establishing Good Manufacturing Practices, report serious adverse events to FDA and register with the agency annually, providing information on ingredients used in their products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Herbalife Expects No ‘Material’ Impact From China Tariff, Recent Deals To Bring ‘New Era’ Of Growth

02 May 2025

• By Malcolm Spicer

Herbalife expects little impact from increased tariffs on imports from China but strong boosts from acquiring Pro2col Health and Pruvit Ventures Inc. and 51% ownership of Link BioSciences.

Fragrance Industry Unification Hedges Against Tariff Impact – Experts

02 May 2025

• By Eileen Francis

Fragrance companies and suppliers can draft contracts that ensure the cost burden of tariffs is shared, says attorney David Morrell of law firm Jones Day, during a recent panel discussion, ‘Tariffs in Motion: Insight for the Fragrance Industry.”

Opella Goes Solo Promising To ‘Redefine The Future Of Self-Care’

01 May 2025

• By Tom Gallen

Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.